Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in Mexico
NNT values for RFS and DMFS data were both lower than the published average NNT value for current melanoma therapies. This demonstrated that fewer additional patients need to be treated in order to avoid a recurrence or a distant metastases event, compared to currently available melanoma therapies. The NNT and COPE highlight the clinical and economic impact of introducing pembrolizumab therapy for the treatment of patients in resected high-risk stage II melanoma.
Authors
- Roberto Acevedo (ORCID: https://orcid.org/0000-0001-6847-0285)
- J. Urrego-Reyes (ORCID: https://orcid.org/0000-0001-8306-8470)
- Mizuho Fukunaga‐Kalabis (ORCID: https://orcid.org/0000-0001-5699-6941)
- Shan Jiang (ORCID: https://orcid.org/0000-0002-3467-8640)
- Robert Hughes (ORCID: https://orcid.org/0000-0001-8446-5865)
- Georgie Weston (ORCID: https://orcid.org/0000-0003-3019-7150)
- Victoria Wurcel (ORCID: https://orcid.org/0000-0003-1330-8963)
- Clemens Krepler
- Ruixuan Jiang (ORCID: https://orcid.org/0000-0003-1737-2989)
- Shujing Zhang (ORCID: https://orcid.org/0000-0001-8956-1725)
- D. Rivera (ORCID: https://orcid.org/0009-0000-0536-125X)
- María Elena Mejía Rojas (ORCID: https://orcid.org/0000-0001-7798-0017)
- Alfredo Caparros
- Nadia Younan
- D.S. Alexander
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Adelphi Group (United Kingdom) (GB)
- MSD (Mexico) (MX)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-03-13
- DOI
- https://doi.org/10.1080/13696998.2025.2466365
- Citations
- 2
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.09